Navigation Links
Ovarian cancer study proves drug delays disease progression, may improve survival
Date:12/28/2011

(TORONTO, Canada Dec. 29, 2011) Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK.

The findings, published today in the New England Journal of Medicine, report that the drug halted the cancer's return for two months overall. However, for women with the highest risk disease, the delay was five to six months and in this group, the findings also indicate a strong trend to improved overall survival, which is being analysed until 2013.

"This is the first new drug in ovarian cancer in 15 years to improve outcome and I believe it should be considered as a potential new standard of care," says Dr. Oza, a medical oncologist who leads the Cancer Clinical Research Unit at Princess Margaret Hospital. He is also co-director of the hospital's Bras Family Drug Development Program and Professor, Faculty of Medicine, University of Toronto.

The seven-year study began in 2004 and enrolled 1,528 women with ovarian cancer at 263 centres, including 20 in Canada. Avastin was added to chemotherapy treatment and given intravenously every three weeks for 12 months.

The drug blocks growth factors that promote new blood vessels formation in tumours, thereby "starving" the cancer. It is not a cure, explains Dr. Oza, but has a proven track record in delaying disease progression in other types of cancer including colorectal, lung, breast, kidney and brain.

"We now know that using Avastin in ovarian cancer for even this short time improves outcomes," says Dr. Oza. "The next step is to determine if giving it for a longer period would be of even greater benefit."

Similar findings from a U.S. study are also reported in this issue of the journal. Dr. Oza says the major difference between the two studies is that the women in the American study were given twice as much Avastin. "So the question now is would half the dose for double the duration improve outcomes even more? This is an area to investigate further."


'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.ca
416-946-2846
University Health Network
Source:Eurekalert

Related medicine news :

1. Targeted therapy extends progression-free survival of patients with advanced ovarian cancer
2. Unique genetic marker may improve detection of recurrent ovarian cancer
3. Mayo Clinic researchers find drug duo kills chemotherapy-resistant ovarian cancer cells
4. Tiny genetic variation can predict ovarian cancer outcome
5. Discovery may help fight late-stage ovarian cancer
6. Vaccine to Treat Breast, Ovarian Cancers Shows Promise
7. Vaccine for metastatic breast, ovarian cancer shows promise
8. Folate receptors may serve as a front door to ovarian cancer treatment
9. Ovarian Tumors May Develop Years After Fertility Therapy
10. Linking of mutations in 12 genes to ovarian cancer may lead to more effective prevention
11. Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... J Thomas & ... continuing it’s commitment to act as Agents of Change in the community, announces ... area homeless families to fulfill immediate needs and help them move into permanent ...
(Date:2/12/2016)... ... February 12, 2016 , ... Nearly every health website and ... These articles generally list between five and 15 foods that should be consumed ... one of these lists and believes that nutritious eye healthy foods are extremely ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners now have a ... CertainTeed, North America’s leading brand of building products, has improved upon its industry-best ... the mobile version of the ColorView® Exterior Style and Color Selector. Created expressly ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... A lot ... past 35 years. A president has access to health and wellness resources most Americans ... free world, no single individual has a schedule as frenetic as the U.S. President. ...
(Date:2/12/2016)... ... , ... The Central Coast Autism Spectrum Center (CCASC) invites teens ages 11-18 to its annual ... for teens with and without special needs to gather in a safe and supportive environment. ... dance will take place on Saturday, Feb. 13 from 7 to 9:30 p.m. at Elks ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Calif. , Feb. 12, 2016  Sequent Medical, ... in a study to evaluate the safety and effectiveness ... the treatment of ruptured intracranial aneurysms.  Prof Laurent ... Hospital, in Paris, France and ... patient. France and Germany.  ...
(Date:2/12/2016)... 2016  OMS Supply, a large provider of oral ... today the recent launching of their new company website. ... features that enhance the user experience and enable practitioners ... --> --> Despite the ... that started in early 2016, they have already made ...
(Date:2/11/2016)... - Cardiac Marker Diagnostic ... and Cancer Therapy. - European Point of Care ... - Key Diagnostic Testing Markets. - Molecular ... Genetic Testing. - Molecular Diagnostics in Infectious Disease ... Diagnostic Products World Markets. - Point of Care ...
Breaking Medicine Technology: